Neoleukin Therapeutics In... (NLTX)
NASDAQ: NLTX
· Real-Time Price · USD
3.49
0.05 (1.45%)
At close: Dec 18, 2023, 10:00 PM
Neoleukin Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -22.65M | -54.33M | -49.02M | -4.53M | -2.08M | -14.2M | -13.45M | -13.07M | -15.69M | -15.35M | -15.17M | -15.45M | -15.13M | -14.95M |
Depreciation & Amortization | 762K | 1.88M | 1.7M | 381K | 371K | 615K | 643K | 590K | 718K | 661K | 631K | 592K | 542K | 512K |
Stock-Based Compensation | 4.05M | 6.63M | 5.33M | 172K | 331K | 1.19M | 2.04M | 2.03M | 2.31M | 2.45M | 3.01M | 3.21M | 2.92M | 2.42M |
Other Working Capital | n/a | -226K | n/a | n/a | n/a | 226K | -2.05M | n/a | n/a | -1.08M | -499K | n/a | n/a | -709K |
Other Non-Cash Items | n/a | -8.66M | -4.32M | -556K | -884K | 3.08M | -379K | n/a | 3K | n/a | -700K | n/a | n/a | n/a |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 700K | n/a | n/a | n/a |
Change in Working Capital | n/a | 5.23M | 1.52M | 260K | -1.78M | -3.71M | 208K | 1.16M | 1.36M | -1.85M | -641K | 2.89M | -1.61M | -1.34M |
Operating Cash Flow | -20.77M | -49.25M | -44.79M | -4.27M | -4.05M | -13.03M | -10.93M | -9.29M | -11.29M | -14.09M | -12.17M | -8.76M | -13.28M | -13.36M |
Capital Expenditures | -780K | -257K | -560K | n/a | -132K | -419K | -104K | -322K | -232K | -452K | -396K | -587K | -1.19M | -1.09M |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | -39.07M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -88.97M | -106.57M | -16.7M | -36.61M | -26.89M | -28.38M | -25.93M | -42.53M | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | -99M | -59.5M | 35M | 24.5M | 39.5M | 34.5M | 15M | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 44.7M | 71.89M | 56.13M | n/a | 2.12M | n/a | 39.07M | n/a | -39.07M | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -45.05M | -133.94M | -20.62M | -1.61M | -411K | 10.71M | 8.47M | -27.85M | -39.3M | -452K | -396K | -587K | -1.19M | -1.09M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | 82K | n/a | n/a | n/a | 372K | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -783K | n/a | n/a | n/a |
Other Financial Acitivies | 19K | 184.75M | -5.44M | -1K | -294K | -66K | 18K | -52K | 62K | 133K | 890K | 32K | 311K | 282K |
Financial Cash Flow | 4K | 184.43M | -5.7M | -1K | -294K | -66K | 18K | -52K | 62K | 133K | 107K | 32K | 311K | 282K |
Net Cash Flow | -65.81M | 111.19M | 41.24M | -5.88M | -4.75M | -2.39M | -2.45M | -37.19M | -50.53M | -14.41M | -12.46M | -9.31M | -14.16M | -14.16M |
Free Cash Flow | -21.55M | -49.51M | -45.35M | -4.27M | -4.18M | -13.45M | -11.04M | -9.61M | -11.53M | -14.54M | -12.56M | -9.34M | -14.47M | -14.45M |